Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer

Blood testing for circulating tumour cells (CTC) has emerged as one of the hottest fields in cancer research. CTC detection and enumeration can serve as a ‘liquid biopsy' and an early marker of response to systemic therapy, whereas their molecular characterisation has a strong potential to be t...

Full description

Bibliographic Details
Main Authors:	Lianidou, E S, Mavroudis, D, Georgoulias, V
Format:	Online
Language:	English
Published:	Nature Publishing Group 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694246/

id	pubmed-3694246
recordtype	oai_dc
spelling	pubmed-36942462013-06-27 Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer Lianidou, E S Mavroudis, D Georgoulias, V Minireview Blood testing for circulating tumour cells (CTC) has emerged as one of the hottest fields in cancer research. CTC detection and enumeration can serve as a ‘liquid biopsy' and an early marker of response to systemic therapy, whereas their molecular characterisation has a strong potential to be translated to individualised targeted treatments and spare breast cancer (BC) patients unnecessary and ineffective therapies. Different analytical systems for CTC detection and isolation have been developed and new areas of research are directed towards developing novel assays for CTC molecular characterisation. Molecular characterisation of single CTC holds considerable promise for predictive biomarker assessment and to explore CTC heterogeneity. The application of extremely powerful next-generation sequencing technologies in the area of CTC molecular characterisation in combination with reliable single CTC isolation opens new frontiers for the management of patients in the near future. This review is mainly focused on the clinical potential of the molecular characterisation of CTC in BC. Nature Publishing Group 2013-06-25 2013-06-11 /pmc/articles/PMC3694246/ /pubmed/23756869 http://dx.doi.org/10.1038/bjc.2013.265 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Lianidou, E S Mavroudis, D Georgoulias, V
spellingShingle	Lianidou, E S Mavroudis, D Georgoulias, V Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer
author_facet	Lianidou, E S Mavroudis, D Georgoulias, V
author_sort	Lianidou, E S
title	Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer
title_short	Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer
title_full	Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer
title_fullStr	Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer
title_full_unstemmed	Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer
title_sort	clinical challenges in the molecular characterization of circulating tumour cells in breast cancer
description	Blood testing for circulating tumour cells (CTC) has emerged as one of the hottest fields in cancer research. CTC detection and enumeration can serve as a ‘liquid biopsy' and an early marker of response to systemic therapy, whereas their molecular characterisation has a strong potential to be translated to individualised targeted treatments and spare breast cancer (BC) patients unnecessary and ineffective therapies. Different analytical systems for CTC detection and isolation have been developed and new areas of research are directed towards developing novel assays for CTC molecular characterisation. Molecular characterisation of single CTC holds considerable promise for predictive biomarker assessment and to explore CTC heterogeneity. The application of extremely powerful next-generation sequencing technologies in the area of CTC molecular characterisation in combination with reliable single CTC isolation opens new frontiers for the management of patients in the near future. This review is mainly focused on the clinical potential of the molecular characterisation of CTC in BC.
publisher	Nature Publishing Group
publishDate	2013
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694246/
_version_	1611989943355179008

Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer

Similar Items